Menu Search
Equities

Collegium Pharmaceutical Inc

354:DUS

Collegium Pharmaceutical Inc

Actions
  • Price (EUR)28.80
  • Today's Change-0.40 / -1.37%
  • Shares traded--
  • 1 Year change+23.08%
  • Beta--
Data delayed at least 15 minutes, as of Nov 26 2024 08:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.

  • Revenue in USD (TTM)599.25m
  • Net income in USD88.59m
  • Incorporated2014
  • Employees197.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		COLL:NSQ since
announced		Transaction
value
Ironshore Pharmaceuticals IncAnnounced29 Jul 202429 Jul 2024Announced-14.55%550.00m
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.